THERAPY DOSSIER · th-04c75b733270

Selenocystine

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 20737246 ↗2010Reported benefit

Hepatoprotective, immunomodulatory, and anti-inflammatory activities of selenocystine in experimental liver injury of rats.

RatChemical/toxinWistarMalen = 40OralBefore CCl4 (pretreatment)

Model: Carbon tetrachloride-induced acute hepatic injury

Selenocystine pretreatment reduced hepatic enzyme leakage, oxidative stress and inflammation in CCl4 liver injury.

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…